Selective activation of peripheral cannabinoid CB 1 receptors has the potential to become a
valuable therapy for chronic pain conditions as long as central nervous system effects are …

Bradyzide is from a novel class of rodent‐selective non‐peptide B 2 bradykinin antagonists (1‐(2‐Nitrophenyl)thiosemicarbazides).
Bradyzide has high affinity for the rodent B 2 receptor…

… The Investigation of transDermal Exelon in ALzheimer's disease (IDEAL) study enrolled
patients with probable AD (Mini-Mental State Examination [MMSE] scores of 10–20). Patients …

The Bradykinin B 2 receptor antagonist HOE 140 (D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg)
has been used as a template for the de novo design and synthesis of a small number …

… primary care consultations for approximately 30% of women, exclusion of all prescription
costs, and the fact that a large proportion of treatment outcomes from two practices (Practices E …

Vanilloid receptor 1 (VR1, TRPV1) is a cation-selective ion channel that is expressed on
primary afferent neurons and is upregulated following inflammation and nerve damage. …

… Presumably, the Boc group, itself directed away from the bulky tertbutyl group, plays a role
in negating the effect of this C-2 stereogenic centre, so that the transition states E and F are …

The Mitsunobu protocol offers a convenient route from imidazole to N-alkyl-substituted
imidazoles, precursors to imidazolium-based ionic liquids, and is particularly useful for …

It has been a decade since the area of bradykinin (BK) research was last reviewed in this
journal. Within this period of time, selective, high-affinity non-peptide BK ligands have been …

The inducible kinin B 1 receptor is emerging as an attractive therapeutic target for the
treatment of pain and inflammation. Although many studies described its regulation at the …